These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 22629832)

  • 21. A new marker of tamoxifen resistance of estrogen receptor-positive breast cancer.
    Bogush EA; Ravcheeva AB; Bogush TA; Zabotina TN; Kadagidze ZG; Davydov MI
    Dokl Biochem Biophys; 2007; 413():83-7. PubMed ID: 17546960
    [No Abstract]   [Full Text] [Related]  

  • 22. Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780).
    Gu Z; Lee RY; Skaar TC; Bouker KB; Welch JN; Lu J; Liu A; Zhu Y; Davis N; Leonessa F; Brünner N; Wang Y; Clarke R
    Cancer Res; 2002 Jun; 62(12):3428-37. PubMed ID: 12067985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells.
    Brinkman A; van der Flier S; Kok EM; Dorssers LC
    J Natl Cancer Inst; 2000 Jan; 92(2):112-20. PubMed ID: 10639512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of ICI 164384 and beta-interferon on the growth and steroid receptor profile of breast cancer cell lines.
    Coradini D; Biffi A; Pirronello E; Di Fronzo G
    Anticancer Res; 1995; 15(6B):2557-61. PubMed ID: 8669823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
    Newby JC; Johnston SR; Smith IE; Dowsett M
    Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The NFkappaB pathway and endocrine-resistant breast cancer.
    Zhou Y; Eppenberger-Castori S; Eppenberger U; Benz CC
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S37-46. PubMed ID: 16113098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estrogen promotes reversible epithelial-to-mesenchymal-like transition and collective motility in MCF-7 breast cancer cells.
    Planas-Silva MD; Waltz PK
    J Steroid Biochem Mol Biol; 2007 Apr; 104(1-2):11-21. PubMed ID: 17197171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of c-myc in tamoxifen-induced apoptosis estrogen-independent breast cancer cells.
    Kang Y; Cortina R; Perry RR
    J Natl Cancer Inst; 1996 Mar; 88(5):279-84. PubMed ID: 8614006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A naringenin-tamoxifen combination impairs cell proliferation and survival of MCF-7 breast cancer cells.
    Hatkevich T; Ramos J; Santos-Sanchez I; Patel YM
    Exp Cell Res; 2014 Oct; 327(2):331-9. PubMed ID: 24881818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
    Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
    Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity.
    Dumont JA; Bitonti AJ; Wallace CD; Baumann RJ; Cashman EA; Cross-Doersen DE
    Cell Growth Differ; 1996 Mar; 7(3):351-9. PubMed ID: 8838865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanism of estrogen-induced apoptosis in breast cancer cells: role of the NF-kappaB signaling pathway.
    Lobanova YS; Scherbakov AM; Shatskaya VA; Krasil'nikov MA
    Biochemistry (Mosc); 2007 Mar; 72(3):320-7. PubMed ID: 17447886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells.
    Madsen MW; Reiter BE; Larsen SS; Briand P; Lykkesfeldt AE
    Cancer Res; 1997 Feb; 57(4):585-9. PubMed ID: 9044830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.
    Pietras RJ; Arboleda J; Reese DM; Wongvipat N; Pegram MD; Ramos L; Gorman CM; Parker MG; Sliwkowski MX; Slamon DJ
    Oncogene; 1995 Jun; 10(12):2435-46. PubMed ID: 7784095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer.
    Fleming FJ; Hill AD; McDermott EW; O'Higgins NJ; Young LS
    J Clin Endocrinol Metab; 2004 Jan; 89(1):375-83. PubMed ID: 14715875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
    Marsaud V; Gougelet A; Maillard S; Renoir JM
    Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Crossroads of estrogen receptor and NF-kappaB signaling.
    Biswas DK; Singh S; Shi Q; Pardee AB; Iglehart JD
    Sci STKE; 2005 Jun; 2005(288):pe27. PubMed ID: 15956359
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
    McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG
    Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor.
    Zajchowski DA; Sager R; Webster L
    Cancer Res; 1993 Oct; 53(20):5004-11. PubMed ID: 8402691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.